

FIG. I




FIG. 2




FIG. 3




FIG. 4a



FIG. 4b



FIG. 4c



FIG. 4d




FIG. 4e



FIG. 4f




FIG. 4g



FIG. 4h

FIGURE 5

**PROTECTION OF DOGS AGAINST COPV
INFECTION BY THE PASSIVE TRANSFER OF IMMUNOGLOBULIN**

TREATMENT PROCEDURE	Number of dogs with tumors	Number of dogs
Infused with lactate Ringers solution	4	4
Infused with non-immune dog serum, 200 mg/kg	4	4
Infused with immune dog serum, 200 mg/kg	0	4

FIGURE 6

DOG VACCINATION STUDIES UTILIZING CONFORMATIONALLY-CORRECT L1 PROTEIN PURIFIED FROM RECOMBINANT-BACULOVIRUS INFECTED Sf9 CELLS

Vaccination Procedure	#dogs with oral tumors
Buffer	6/8
Formaline-fixed wart extract	0/8
L1	0/8
L1 + alum adjuvant	0/8
L1 + QS21 adjuvant	0/8

Exp. COPV#1 VLP
 4/6/94: Coating Ag=isolated COPV particles. Dog sera: 1:100 dilutions of pooled (n=8) samples.
 KGP 2° (anti-IgG) at 1:200. Rabbit sera at 1:500, KGP 2° at 1:1000. 30 minute reading
 Normal Rabbit serum was 0.080.





FIGURE 7

antibody response against COPV conformational epitopes

FIGURE 8

antibody response against COPV linear epitopes



Exp. COPV #1:L1 VLP
 4/6/94; Coating Ag-Recombinant L1(Insoluble). Dog sera: 1:100 dilutions of pooled (n=8) samples.
 Behy 2° (anti-IgG) at 1:500. Rabbit sera at 1:500, KGP 2° at 1:1000. 30 minute reading
 Normal Rabbit serum was 0.080.